Close Menu

NEW YORK (GenomeWeb) – Arcis Biotechnology is aiming to raise £2 million (about $2.8 million) in a financing round to further develop a multiplex RNA-biomarker prostate cancer screening test.

The UK-based firm plans to use raised funds to finalize the prostate cancer test for use with patient urine samples by using its proprietary technology for stabilization of genetic material. Acris has already raised about £690,000 in capital for the assay.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.